The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease

Summary Pneumococcal conjugate vaccines (PCVs) are a potentially useful complement to existing treatment strategies in HIV-infected children, for whom pneumococcal infections are common and serious. This Review summarises available data on the burden of pneumococcal disease and the safety and effica...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2008, Vol.8 (1), p.67-80
Main Authors: Bliss, Sandra J, Dr, O'Brien, Katherine L, MD, Janoff, Edward N, Prof, Cotton, Mark F, MBChB, Musoke, Philippa, MBChB, Coovadia, Hoosen, Prof, Levine, Orin S, PhD
Format: Article
Language:English
Subjects:
AIDS-Related Opportunistic Infections - microbiology
AIDS-Related Opportunistic Infections - prevention & control
Antiretroviral Therapy, Highly Active - methods
Bacterial diseases
Biological and medical sciences
Child
HIV
HIV Infections - immunology
HIV Infections - microbiology
Human bacterial diseases
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious Disease
Infectious diseases
Medical sciences
Pneumococcal Infections - prevention & control
Pneumococcal Infections - virology
Pneumococcal Vaccines - immunology
Pneumococcal Vaccines - therapeutic use
Staphylococcal infections, streptococcal infections, pneumococcal infections
Streptococcus pneumoniae - immunology
Vaccines
Vaccines, Conjugate - immunology
Vaccines, Conjugate - therapeutic use
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Pneumococcal conjugate vaccines (PCVs) are a potentially useful complement to existing treatment strategies in HIV-infected children, for whom pneumococcal infections are common and serious. This Review summarises available data on the burden of pneumococcal disease and the safety and efficacy of PCVs in HIV-infected children. The data demonstrate that children with HIV have significantly increased risk of pneumococcal disease compared with uninfected children; the serotypes included in currently licensed or near-licensure conjugate vaccines include most serotypes that cause invasive pneumococcal disease (IPD) in HIV-infected children and adults; PCVs provide substantial protection against IPD and clinical pneumonia when given to HIV-infected infants; and HIV-infected adults gain an indirect benefit when children in the community are vaccinated. PCV should be considered as an important intervention for improving the lives of HIV-infected children.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(07)70242-6